Hookipa pharma (HOOK), a biopharmaceutical company specializing in immunotherapies, announced that the first person has been dosed in a Phase 1b clinical trial of HB-500 for the treatment of HIV.
HB-500 is being developed in collaboration with Gilead Sciences Inc. (GILD). This investigational therapeutic vaccine for the treatment of HIV comprises two genetically engineered replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively.
The phase Ib trial of HB-500 includes two dose escalation cohorts that will be randomized to receive HB-500 or placebo.
While HOOKIPA will oversee the advancement of the HIV program through the completion of the Phase 1b clinical trial, Gilead holds exclusive rights for further development of the program.
The patient dosing in the Phase 1b clinical trial of HB-500 for triggers a $5 million non-dilutive milestone payment for Hookipa under its collaboration and license agreement with Gilead.
HOOK has traded in a range of $0.41 to $1.13 in the last 1 year. The stock closed Yesterday' s trading (July 1, 2024) at $6.28, up 6.17% during afterhours the stock was at $0.61, down 2.10%.
For comments and feedback: editorial@rttnews.com